medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2014, Number 6

<< Back Next >>

Rev Invest Clin 2014; 66 (6)

In vitro determination of the short-chain synthetic peptide RP13 antimicrobial activity

Sánchez A, Calderón E, Castañón-Alonso SL, Santos A, Hernández B, Vázquez A

Language: English
References: 37
Page: 527-533
PDF size: 159.11 Kb.


ABSTRACT

Background. The proliferation of antibiotic-resistant microorganisms, along with the lack of new drugs against them, has elicited the interest of the scientific community on the study and development of endogenous synthetic compounds with bacteriostatic or bactericidal activity. In recent years, several short-chain, low molecular weight peptides isolated from natural sources such as plants and animals have demonstrated an array of antimicrobial activities. Despite having structural characteristics similar to microbicidal peptides isolated from human platelets, peptide RP11 does not exhibit antimicrobial activity. Objective. In vitro determination of the antimicrobial activity of the synthetic peptide RP13. Material and methods. Peptide RP13 was prepared modifying the original amino acids sequence of peptide RP11, reversing the position of the amino acids lysine and tyrosine in order to modify the conformation of the original peptide. These amino acids are localized close to the N-terminus of the peptidic chain. Peptide RP13 was prepared in solution using conventional methods for peptide synthesis. The antimicrobial activity of RP13 was assessed against the microorganisms S. aureus, E. faecalis and E. coli in a test solution and later evaluated by cultivation of plates during the first 2 h after inoculation of bacteria. RP13 activity antimicrobial was compared against tetracycline, a broad-spectrum antibiotic. Results. The new peptide RP13, resulting form the structural modification of the amino acid sequence of peptide RP11, displayed antimicrobial activity. RP13 demonstrated to be more efficient inhibiting the growth of gram-positive than gramnegative bacteria. Conclusions. The structural modification of peptide RP11, obtained from human platelets, resulted in a new peptide with improved antimicrobial activity. These results clearly demonstrate that peptides of natural origin, as well as their synthetic analogs, represent an attractive alternative against pathogenic agents.


REFERENCES

  1. Travis J. Reviving the antibiotics miracle? Science 1994; 264: 360-2.

  2. Neuhauser MM, Weinstein RA, Rydman R. Antibiotic resistance among gram negative bacilli in us intensive care units: implications for fluoroquinoline use. JAMA 2003; 289: 885-8.

  3. Hancock RW. Peptide Antibiotics. Lancet 1997; 349: 418-22.

  4. Boman HG. Peptides antibiotics and their role in innate immunity. Annu Rev Immunol 1995; 13: 61-92.

  5. Hancock RW. Cationic peptides: effectors innate immunity and novel antimicrobials. Lancet 2001; 1: 156-64.

  6. Boman HG. Antibacterial peptides: basic facts and emerging concepts. J Intern Med 2003; 254: 197-215.

  7. Yeaman MR. The role of platelets in antimicrobial host defense. Clin Infect Dis 1997; 25: 951-68.

  8. Dürr M, Peschel A. Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense. Infect Immun 2002; 70: 6515-7.

  9. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003; 55: 27-55.

  10. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3: 238-50.

  11. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun 2002; 70: 6224-533.

  12. Yount N. Platelet microbicidal protein 1: Structural themes of a multifunctional antimicrobial peptide. Antimicrob Agents Chemother 2004; 48: 4395-404.

  13. Raj PA, Dentino AR. Current status of defenses and their role in innate and adaptative immunity. FEMS Microbiol Lett 2002; 206: 9-18.

  14. Jensen H, Mamill P, Hancock RW. Peptide antimicrobial agents. Clin Microbiol Rev 2006; 19: 491-511.

  15. Marshall SH, Arenas G. Antimicrobial peptides: a natural alternative to chemical antibiotics and a potential for applied biotechnology. Electron J Biotechnol 2003; 6: 271-84.

  16. Darveu RP, Blake J, Seachord CL, et al. Peptides related to the carboxyl terminus of human platelet factor IV with antibacterial activity. J Clin Invest 1992; 90: 447-55.

  17. Yeaman MR, Gank KD, Bayer AS, Brass EP. Synthetic peptides that exert antimicrobial activities in whole blood-derived matrices. Antimicrob Agents Chemother 2002; 46: 3883-91.

  18. Yeaman MR, Puentes SM, Norman DC, et aler ASDC, Bayer AS, Brass. Partial characterization and staphylocidal activity of thrombin-induced platelet microbicidal protein. Infect Immun 2002; 60: 1201-09.

  19. Wuts PG, Greene T. Greene’s Protective Groups in Organic Synthesis. 4th ed. New York: Wiley Interscience; 2006, p. 1082.

  20. Sewald N, Jakubke H. Peptides: Chemistry and Biology. 2nd Ed. Weinheim, Germany: Wiley-VCH; 2009, p. 578.

  21. Bodansky M, Bodansky A. The Practice of Peptide Synthesis. 4th Ed. Berlin: Springer-Verlag; 1994, p. 217.

  22. Hancock RW, Lether RI. Cationic peptides: a new source of antibiotics. Trends Biotechnol 1998; 16: 82-8.

  23. Harwig SL, Ganz T, Lehrer RI. Neutrophil defensins: purification, characterization and antimicrobial testing. Methods Enzymol 1994; 236: 160-72.

  24. Koczulla AR, Bals R. Antimicrobial peptides: current status and therapeutic potential. Drugs 2003; 63: 389-406.

  25. Yeaman MR, Ibrahim As, Edwards JE, et al. Thrombin-induced rabbit platelet microbicidal protein is fungicidal in vitro. Antimicrobial Agents Chemother 1993; 37: 546-54.

  26. Giangaspero A, Sandri L, Tossi A. Amphipathic á helical antimicrobial. Eur J Biochem 2001; 268: 5589-600.

  27. Sharma RK, Sundriyal S, Wangoo N, et al. New antimicrobial hexapeptides: synthesis, antimicrobial activities, cytotoxicity and mechanistic studies. Chem Med Chem 2010; 5: 86-95.

  28. Oh JE, Hong SY, Lee KH. Structure-activity relationship study: short antimicrobial peptides. J Pept Res 1999; 53: 41-6.

  29. Schriever C, Fernández C, Rodvold KA, et al. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 2005; 62: 1145-54.

  30. Maisetta G, Batoni G, Esin S, et al. In vitro bactericidal activity of human β-defensin 3 against multidrug-resistant nosocomial strains. Antimicrob Agents Chemother 2006; 50: 806-09.

  31. Azuma M, Kojima T, Tokoyama I, et al. A synthetic peptide of human apoprotein E with antibacterial activity. Peptides 2000; 21: 327-30.

  32. Jang WS, Kim KN, Park SY, et al. Biological activities of synthetic analogs of halocidine, an antimicrobial peptide from the tunicate. Antimicrob Agents Chemother 2003; 47: 2481-6.

  33. Krigsveld J, Zaat SA, Meeldijk J, et al. Thrombocidins, microbicidal proteins from blood platelets, are C-terminal deletion products of CXC chemokines. J Biol Chem 2000; 275: 20374- 85.

  34. Xiong YQ, Bayer AS, Yeaman MR. Inhibition of intracellular macromolecular synthesis in Staphylococcus aureus by thrombin-induced platelet microbicidal proteins. J Infect Dis 2002; 185: 346-56.

  35. Janieszewska J, Swieton J, Lipkowski W, et al. Low molecular mass peptide dendrimers that express antimicrobial properties. Bioorg Med Lett 2003; 13: 3711-3.

  36. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-95.

  37. Ericksen B, Wu Z, Wu Y, et al. Antibacterial activity and specificity of the six human α-defensins. Antimicrob Agents Chemother 2005; 49: 269-75.




2020     |     www.medigraphic.com